Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs Teleios Health

PlexusDx
Graded #158

Higher grade

vs+7.5
Teleios Health
Graded #327

Lower grade

The verdict

PlexusDx takes it — 67.7/100 to 60.2/100.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +10
74
84
Dose & formulationEven
64
64
Clinical oversightPlexusDx +25
74
49
Labs & monitoringPlexusDx +4
52
48
FulfillmentPlexusDx +36
78
42
Contract termsEven
55
55
PlexusDx · left barTeleios Health · right bar

The numbers

MetricPlexusDxTeleios Health
WeighScore67.7/10060.2/100
GradeCC
Scorecard rank#158#327
Semaglutide$149/mo (starting dose, compounded)$99/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$139/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
PlexusDx

Graded #158 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted
Teleios Health

Graded #327 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard